All In Biotech

Drug Trial Radar · NCT07073534

Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors

Phase I/II Clinical Study on the Tolerability, Safety and Efficacy of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors

Last checked: Nov 19, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

203

Planned (sponsor's estimate)

Start

Jul 24, 2025

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Jul 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open, multicenter phase I/II clinical study. The entire study is divided into three stages: dose escalation, dose expansion, and efficacy expansion. Objective: To evaluate the objective response rate (ORR), safety and tolerability of the combination of SHR-1501 and adibelizumab in the treatment of advanced malignant tumors, and to provide the recommended dose (RP2D) for subsequent clinical studies.

Conditions

  • Patients With Advanced or Metastatic Malignant Tumors

Interventions

  • SHR-1501, AdebrelimabDrug

    the combination of SHR-1501 and Adebrelimab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicityTime frame: 21 Days or 28 days
  2. Maximum tolerated dose or Maximum-administered doseTime frame: Approximately 1 years
  3. Recommended Phase 2 dose (RP2D)Time frame: Approximately 2years.
  4. Objective response rate(ORR)Time frame: Approximately 2 years
  5. The incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0)Time frame: 21 Days,Approximately 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.